Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

                                   May 5, 2005
                Date of Report (Date of earliest event reported)

                                 ANTIGENICS INC
             (Exact name of registrant as specified in its charter)

          DELAWARE                        000-29089               06-1562417
(State or other jurisdiction            (Commission             (IRS Employer
      of incorporation)                 File Number)         Identification No.)

              630 Fifth Avenue, Suite 2100
                   New York, NY 10111                            10111
        (Address of principal executive offices)               (Zip Code)

              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act 
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act 
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the 
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the 
    Exchange Act (17 CFR 240.13e-4(c))

Item 2.02         Results of Operations and Financial Condition

                  On May 5, 2005, Antigenics Inc. announced its financial
                  results for the quarter ended March 31, 2005. The full text of
                  the press release issued in connection with the announcement
                  is being furnished as Exhibit 99.1 to this current report on
                  Form 8-K.

Item 9.01         Financial Statements and Exhibits

         (c) Exhibits:

                  99.1     Press Release dated May 5, 2005


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                                 ANTIGENICS INC.

Date: May 5, 2005

                                                           By: /s/ Garo H. Armen
                                                            Garo H. Armen, Ph.D.
                                            Chairman and Chief Executive Officer


The following designated exhibits are filed herewith:


99.1                       Press Release dated May 5, 2005